HR 2855
117th Congress
House
Health
Health care costs and insurance
Health care coverage and access
Health care quality
Health programs administration and funding
Medicare
Performance measurement
Prescription drugs
Star Rating for Biosimilars Act
Everywhere this bill has been
5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 27, 2021
Referred to the Subcommittee on Health.
Apr 26, 2021
Referred to the Subcommittee on Social Security.
Apr 26, 2021
Referred to the Subcommittee on Health.
Apr 26, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 26, 2021
Introduced in House
Plain-English summary
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
5